{"id":391568,"date":"2014-08-29T00:00:00","date_gmt":"2014-08-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorid0214-biopharma-hospital-treated-gram-negative-infections-pharmacor-g7-2014\/"},"modified":"2026-03-31T09:04:48","modified_gmt":"2026-03-31T09:04:48","slug":"pcorid0214-biopharma-hospital-treated-gram-negative-infections-pharmacor-g7-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorid0214-biopharma-hospital-treated-gram-negative-infections-pharmacor-g7-2014\/","title":{"rendered":"Hospital-Treated Gram-Negative Infections | Pharmacor | G7 | 2014"},"content":{"rendered":"<p>Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these infections. In the past developers have focused heavily on anti-gram-positive therapies, like those against MRSA, which has allowed the number of antibiotics for GNIs in late-stage pipeline to dwindle. Therefore, the GNI market provides wide market opportunity for developers that can tackle segments of unmet need. In particular, rising multidrug resistance (MDR) in key gram-negative pathogens (GNPs) (e.g., <em>Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli,<\/em> and <em>Klebsiella pneumoniae<\/em>) leave physicians with limited therapeutic options. With fewer alternatives, high volume use of a few current agents creates selective pressure for the further development of drug-resistance to therapy. Therefore, opportunity awaits developers who can provide therapies that not only overcome drug-resistance to current therapies, but are safe and tolerable and can stave off emergence of antibiotic-resistance by using novel mechanisms of action.<\/p>\n","protected":false},"template":"","class_list":["post-391568","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391568\/revisions"}],"predecessor-version":[{"id":394691,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391568\/revisions\/394691"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}